证券代码：688236 证券简称：春立医疗 公告编号：2025-033 北京市春立正达医疗器械股份有限公司 关于与私募基金合作投资的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： ● 投资基金名称及投资方向，与上市公司主营业务相关性：北京市春立正达 医疗器械股份有限公司（以下简称"公司"）与南昌德福投资咨询合伙企业（有 限合伙）及其他合伙人共同投资南昌德福四期股权投资基金合伙企业（有限合伙） （以下简称"合伙企业"）。合伙企业的投向主要为医疗健康产业相关领域的处 于成长期、成熟期的企业/项目，与公司主营业务具有相关性。 ● 投资金额、在投资基金中的占比及身份：公司作为有限合伙人以自有资金 5,000 万元人民币参与认购合伙企业的份额，占基金份额的 9.2105%。 ● 相关风险提示： 1、本次交易后续尚需履行工商登记、基金备案等程序，具体实施情况和进度上 存在不确定性，公司将及时披露进展情况。敬请投资者注意投资风险。 2、公司作为基金的有限合伙人承担的风险敞口以投资额为限，本次投资无保本 及最低收益承 ...

Group 1 - The company Spring Medical (688236.SH) announced a partnership with Nanchang Defu Investment Consulting Partnership to invest in a private equity fund [1] - The total committed capital of the partnership is 542.857143 million yuan, with the company contributing 50 million yuan, representing 9.2105% of the total [1] - The investment focus of the partnership will be on growth and mature stage enterprises/projects in the healthcare industry [1]

Core Viewpoint - Spring Medical (688236.SH) has signed a partnership agreement with Nanchang Defu Investment Consulting Partnership and other partners to invest in the healthcare industry [1] Group 1: Investment Details - The total subscribed capital of the partnership is 542.857143 million yuan, with the company contributing 50 million yuan, accounting for 9.2105% of the total subscribed capital [1] - The investment targets of the partnership focus on enterprises/projects in the healthcare industry that are in the growth or mature stages [1]

FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年7月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 北京市春立正達醫療器械股份有限公司 呈交日期: 2025年8月6日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01858 | 說明 | H股 | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 95,140,500 | RMB | | 1 RMB | | 95,140,500 | | 增加 / 減少 (-) | | | 0 | | | RMB | | 0 | | 本月底結存 | | | 95,140,500 | RMB | | 1 RMB | | 95,140,500 | | 2. 股份分類 | 普通股 | 股份類別 ...

FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年7月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 北京市春立正達醫療器械股份有限公司 第 1 頁 共 10 頁 v 1.1.1 呈交日期: 2025年8月6日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01858 | 說明 | H股 | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 95,140,500 | RMB | | 1 RMB | | 95,140,500 | | 增加 / 減少 (-) | | | 0 | | | RMB | | 0 | | 本月底結存 | | | 95,140,500 | RMB | | 1 RMB | | 95,140,500 | | ...

Group 1 - The stock price of Chunzhi Medical reached 22.01 yuan as of August 5, 2025, with an increase of 0.24 yuan, representing a rise of 1.10% from the previous trading day [1] - The opening price for the day was 21.75 yuan, with a highest point of 22.35 yuan and a lowest point of 21.44 yuan, resulting in a trading volume of 26,013 hands and a transaction amount of 0.57 billion yuan [1] - Chunzhi Medical operates in the medical device industry, focusing on the research, production, and sales of orthopedic implant medical devices, covering areas such as joints, spine, and trauma [1] Group 2 - As of August 5, the net inflow of main funds was 3.3956 million yuan, accounting for 0.05% of the circulating market value [1] - However, over the past five trading days, there was a cumulative net outflow of 10.5961 million yuan, which represents 0.17% of the circulating market value [1]

来源：新浪证券-红岸工作室 8月5日，春立医疗涨1.10%，成交额5694.25万元，换手率0.90%，总市值84.42亿元。 异动分析 智能医疗+牙科医疗+医疗器械概念+专精特新+京津冀一体化 1、2024年10月9日互动易：我公司是一家专注于骨科医疗器械领域的高新技术企业，产品涵盖关节类、 脊柱类、运动医学类、创伤类等全系列骨科产品。同时公司已经取得了髋关节手术机器人、膝关节手术 机器人等产品的注册证，以及手术规划的"医学图像处理软件"。这些产品和软件的开发表明公司在智能 医疗等领域进行的布局和研发投入。 2、国内领先的骨科医疗器械厂商，春立医疗主营业务系植入性骨科医疗器械的研发、生产与销售，包 括口腔金属和隐形正畸 口腔种植和修复。 公司拟设计多孔钽定制个体化牙种植体产品并完成生产转 换， 目前处于设计送检阶段。 3、公司是国内领先的骨科医疗器械厂商，主营业务系植入性骨科医疗器械的研发、生产与销售。公司 主要产品为关节假体产品及脊柱类植入产品，其中关节假体产品涵盖髋、膝、肩、肘四大人体关节，脊 柱类植入产品为脊柱内固定系统的全系列产品组合。 4、专精特新"小巨人"企业是全国中小企业评定工作中最高等级、最 ...

证券之星消息，截至2025年8月4日收盘，春立医疗(688236)报收于21.77元，上涨2.4%，换手率1.15%， 成交量3.33万手，成交额7205.17万元。 8月4日的资金流向数据方面，主力资金净流入373.26万元，占总成交额5.18%，游资资金净流出0.02万 元，散户资金净流出373.24万元，占总成交额5.18%。 近5日资金流向一览见下表： | | | | | 日期 收盘价 涨跌幅 主力净流入 主力净占比 游资净点比 散户净流入 散户净占比 | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 2025-08-04 | 21.77 | 2.40% | 373.26万 | 5.18% | -168.00 | 0.00% | -373.24万 | -5.18% | | 2025-08-01 | 21.26 | -3.67% | -1068.88万 | -15.67% | -207.65万 | -3.04% | 1276.52万 | 18.72% | | 2025-07-31 | 22.12 -1.69% | | ...

Group 1 - The core viewpoint of the article highlights that Chunzhi Medical's stock closed at 21.77 yuan, with a 2.40% increase, resulting in a rolling PE ratio of 65.31 times and a total market value of 8.35 billion yuan [1] - The average PE ratio for the medical device industry is 54.32 times, with a median of 38.11 times, placing Chunzhi Medical at the 90th position in the industry ranking [1] - As of March 31, 2025, Chunzhi Medical has 7,167 shareholders, an increase of 501 from the previous count, with an average holding value of 352,800 yuan and an average holding quantity of 27,600 shares [1] Group 2 - Chunzhi Medical specializes in the research, production, and sales of implantable orthopedic medical devices, including spinal, trauma, joint, sports medicine, bone repair materials, surgical instruments, and PRP preparation kits [1] - The latest quarterly report for Q1 2025 shows that the company achieved an operating income of 230 million yuan, a year-on-year increase of 3.60%, and a net profit of 58.07 million yuan, a year-on-year increase of 5.20%, with a gross profit margin of 66.69% [1]

Group 1 - The stock price of Chunli Medical as of July 31, 2025, closed at 22.12 yuan, down by 0.38 yuan, representing a decline of 1.69% from the previous trading day [1] - The trading volume on that day was 30,700 lots, with a transaction value of 0.69 billion yuan, and the stock experienced a fluctuation of 5.56% [1] - Chunli Medical specializes in the research, development, production, and sales of orthopedic medical devices, covering areas such as joints, spine, and trauma [1] Group 2 - The company announced a cash dividend plan for the fiscal year 2024, proposing a distribution of 0.49 yuan per 10 shares, with the record date set for July 31 [1] - On July 31, Chunli Medical experienced a net outflow of main funds amounting to 8.61 million yuan, which accounted for 0.13% of its circulating market value [1]